Headed to the Festival of Biologics in Basel this October?  We’re exhibiting in booth #409 and presenting on Day 2 of the event at 2:10pm, so make sure to schedule time with our experts in complex biologic & bioconjugate drug development while you’re there!

Our attending development experts include our VP of Research & Innovation, Dr Rob Holgate, Sr. Director of R&D Business Development, Dr Ji-won Choi, and Director of R&D Business Development, Lawrence Welch.

Presentation Details: Day 2 at 2:10pm 

Title: “Integrating Stable Pools into Your Developability Strategy to Select Better Lead Candidates & Accelerate Development Timelines.”

Speaker: Dr Rob Holgate, VP of Research & Innovation

Abstract:

As biologic modalities become increasingly complex, selecting candidates based on biology alone is no longer sufficient. Successful development depends on balancing therapeutic potential with critical developability and manufacturability attributes, including stability, productivity and product quality. Yet many of these factors are assessed only after clonal cell lines are established, when key candidate selection decisions have already been made.

Integrating stable pools into the developability strategy helps close this disconnect by providing manufacturing-relevant insights that improve decision-making and reduce downstream risk much earlier than has traditionally been possible. Stable pools can be generated rapidly and provide material that better reflects eventual manufacturing performance than transient expression systems, enabling multiple candidates to be evaluated in parallel for developability, product quality, and manufacturability.

Dr. Rob Holgate, VP of Research & Innovation at Abzena, will discuss how an integrated approach that combines stable pool assessment, developability evaluation, and advanced cell line development increases the probability of technical success, accelerates development timelines, and supports the efficient advancement of next-generation biologics from discovery to clinical and commercial manufacture. The presentation will also highlight how Abzena’s AbZelectPRO™ platform supports diverse and challenging molecular formats while delivering high-producing, genetically stable cell lines suitable for scalable manufacturing.

Schedule a Meeting